Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced a two-year strategic partnership with Xilio Therapeutics. Applied BioMath will provide a variety of services related to mathematical modeling, simulation, analysis, and visualization, which include syste
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced a collaboration with Cullinan Oncology. Applied BioMath will develop a systems pharmacology model for CLN-049, a novel FLT3XCD3 bispecific antibody for Acute Myeloid Leukemia, being developed by Cullinan Florentine, a Cullinan Oncology company.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced their participation at the World Bispecific Summit occurring virtually September 22-24, 2020.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced that due to COVID-19 they will hold their fourth annual Quantitative Systems Pharmacology (QSP) Summit virtually on November 5, 2020 from 9 a.m. - 5 p.m.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced a collaboration with Flame Biosciences. Flame Biosciences selected Applied BioMath to develop systems pharmacology models for Flame Bioscience's leading therapeutic for the treatment of cancers that are driven by inflammation.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced their participation at the Cell Engager Summit occurring virtually August 18 - 20, 2020.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced their collaboration with Verseau Therapeutics for the development and delivery of a systems pharmacology model that will be used for efficacious dose prediction for the treatment of cancer.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced their participation at the Third Annual Next-Gen Immuno-oncology Congress occurring virtually June 25-26, 2020.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced they have entered a two-year strategic partnership with
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced they have been awarded a grant for the development of a software platform called Antibody Drug Conjugate (ADC) Workbench to facilitate efficient knowledge discovery and enable rapid knowledge qualificati
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced that it is creating a systems pharmacology model to support ongoing research into the compassionate care use of tissue plasminogen activator (tPA) as treatment of respiratory distress for patients with A
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced the continuation of their collaboration with Zymeworks Inc. Applied BioMath will design and deliver a systems pharmacology model for a therapeutic platform Zymeworks has in development.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced a collaboration with Xilio Therapeutics.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced a collaboration with Northern Biologics for semi-mechanistic pharmacokinetic and pharmacodynamic (PK/PD) modeling of Northern Biologics' lead preclinical antibody for the treatment of cancer. Northern Biologics will leverage Applied Biomath's modelling expertise to strengthen their understanding of key biological a
Applied BioMath, LLC, the industry leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced a collaboration with OncoMyx Therapeutics, a priv
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced their upcoming webinar, "Translational Modeling Strategies to Predict Clinical Doses for CD3 Bispecific Molecules'' occurs Thursday, March 12, 2020 at 2p.m. ET / 11a.m. PT.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced their participation at the Festival of Biologics occurring March 2-4, 2020 in San Diego, CA.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced a collaboration with Gritstone Oncology, Inc. for semi-mechanistic systems pharmacology modeling. Applied BioMath created a semi-mechanistic pharmacokinetic, receptor occupancy model for a Gritstone Oncology, Inc.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced their upcoming webinar, "Model-Based Approach to Design Bispecific Modalities in Early Discovery" occurs Tuesday, February 4, 2020 at 2p.m. ET / 11a.m. PT.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced their fourth annual Quantitative Systems Pharmacology (QSP) Summit will occur May 20-21, 2020 at the MIT Samberg Conference Center in Cambridge, MA.
Helen Moore has been appointed Council at Society for Industrial and Applied Mathematics (SIAM).
Helen Moore, Director of Applied Mathematics at Applied BioMath, will use her position to proactively address challenges including decisions that need to be made about ethics issues, open access journal policies, declining journal subscriptions, and emerging platforms for communicating research results. Moore currently serves on SIAM's Council.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced their participation at The Society for Immunotherapy of Cancer (SITC) occurring November 6th-10th in National Harbor, Maryland. They will present two posters at the conference Friday, November 8th.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced their participation at PharmSci 360 occurring November 3-6, 2019 in San Antonio, Texas.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development,
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced they will host Quantitative Systems Pharmacology (QSP) Day November 12, 2019 from 2-7p.m. at the AC Hotel by Marriott San Francisco Airport/Oyster Point Waterfront in South San Francisco, CA.